Modern methods of treatment of elderly patients with chronic heart failure: a literature review

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Chronic heart failure (CHF) is the final stage in the development of cardiovascular diseases. Its development is directly associated with the age of patients. Patients with CHF are recommended to prescribe drugs that stabilize the clinical condition and improve the long-term prognosis. However, elderly patients are underrepresented in randomized controlled trials of CHF, which limits the possibility of generalizing the results of studies in real clinical practice for elderly patients with CHF. Older age and the presence of frailty are factors that limit the prescription of recommended drugs and lead to lower adherence to optimal drug therapy in elderly patients. The review analyzes the results of original studies on the problems of the current state of optimal drug therapy for patients with CHF, including in older patient populations, as well as some interventions that may help improve adherence to evidence-based recommendations in older age groups.

Full Text

Restricted Access

About the authors

Olga N. Kurochkina

Pitirim Sorokin Syktyvkar State University

Author for correspondence.
Email: olga_kgma@mail.ru
ORCID iD: 0000-0003-1595-7692

Dr. Sci. (Med.), Professor, Department of Therapy, Medical Institute

Russian Federation, Syktyvkar

A. V. Baranov

Pitirim Sorokin Syktyvkar State University; Northern State Medical University

Email: olga_kgma@mail.ru
Russian Federation, Syktyvkar; Arkhangelsk

A. S. Sazhina

Pitirim Sorokin Syktyvkar State University

Email: olga_kgma@mail.ru
ORCID iD: 0000-0002-0741-9053
Russian Federation, Syktyvkar

A. N. Bogomolov

St. Petersburg Institute of Bioregulation and Gerontology; City Alexander Hospital

Email: olga_kgma@mail.ru
ORCID iD: 0000-0003-0019-0820
Russian Federation, St. Petersburg; St. Petersburg

References

  1. Терещенко С.Н., Галявич А.С. и др. Клинические рекомендации Российского кардиологического общества. Хроническая сердечная недостаточность (ХСН). 2020. [Tereshchenko S.N., Galyavich A.S., et al. Clinical recommendations of the Russian Society of Cardiology. Chronic heart failure (CHF). 2020. (In Russ.)]. URL: https://scardio.ru/content/Guidelines/2020/Clinic_rekom_HSN-unlocked.pdf
  2. Поляков Д.С., Фомин И.В., Беленков Ю.Н. и др. Хроническая сердечная недостаточность в Российской Федерации: что изменилось за 20 лет наблюдения? Результаты исследования ЭПОХА–ХСН. Кардиология. 2021;61(4):4–14 [Polyakov D.S., Fomin I.V., Belenkov Yu.N., et al. Chronic heart failure in the Russian Federation: what has changed over 20 years of follow-up? Results of the EPOCH-CHF study. Kardiologiia. 2021;61(4):4–14. (In Russ.)]. doi: 10.18087/cardio.2021.4.n1628.
  3. Urbich M., Globe G., Pantiri K., et al. A Systematic Review of Medical Costs Associated with Heart Failure in the USA (2014–2020). Pharmacoeconomics. 2020;38(11):1219–36. doi: 10.1007/s40273-020-00952-0.
  4. Lesyuk W., Kriza C., Kolominsky-Rabas P. Cost-of-illness studies in heart failure: a systematic review 2004–2016. BMC Cardiovasc Disord. 2018;18(1):74. doi: 10.1186/s12872-018-0815-3.
  5. Mamas M.A., Sperrin M., Watson M.C., et al. Do patients have worse outcomes in heart failure than in cancer? A primary care-based cohort study with 10-year follow-up in Scotland. Eur J Heart Fail. 2017;19(9):1095–1104. doi: 10.1002/ejhf.822.
  6. Драпкина О.М., Палаткина Л.О. Новые акценты в изучении патогенеза хронической сердечной недостаточности с сохраненной фракцией выброса: фокус на маркеры воспаления. Рациональная фармакотерапия в кардиологии. 2014;10(3):317–21. [Drapkina O.M. Palatkina L.O. New focuses in the study of the pathogenesis of chronic heart failure with preserved ejection fraction: focus on markers of inflammation. Ratsional’naya farmakoterapiya v kardiologii. 2014;10(3):317–21. (In Russ.)]. doi: 10.20996/1819-6446-2014-10-3-317-321.
  7. Яковлева Н.Ф., Маянская С.Д., Яковлев А.В. и др. Влияние полиморфных вариантов гена эндотелиальной синтазы окиси азота на развитие и течение хронической сердечной недостаточности. Кардиоваскулярная терапия и профилактика. 2018;7(5):56–61. [Yakovleva N.F., Mayanskaya S.D., Yakovlev A.V. Influence of polymorphic variants of the endothelial nitric oxide synthase gene on the development and course of chronic heart failure. Kardiovaskulyarnaya terapiya i profilaktika. 2018;7(5):56–61. (In Russ.)].
  8. Bielecka-Dabrowa A., Ebner N., Dos Santos M.R., Ishida J., Hasenfuss G., von Haehling S. Cachexia, muscle wasting, and frailty in cardiovascular disease. Eur J Heart Fail. 2020;22(12):2314–26. doi: 10.1002/ejhf.2011.
  9. Pandey A., Kitzman D., Reeves G. Frailty is intertwined with heart failure: mechanisms, prevalence, prognosis, assessment, and management. JACC Heart Fail. 2019;7(12):1001–11. doi: 10.1016/j.jchf.2019.10.005
  10. Sato R., Vatic M., da Fonseca, G.V., et al. Sarcopenia and weakness in heart failure: is there a biomarker signature? Curr Heart Fail Rep. 2022;19:400–11. doi: 10.1007/s11897-022-00575-w.
  11. Yin J., Lu X., Qian Z., et al. New understanding of the pathogenesis and treatment of sarcopenia in chronic heart failure. Theranostics. 2019;9(14):4019–29. doi: 10.7150/thno.33000.
  12. Ren Z. Effects of Chronical Heart Failure on Longitudinal Changes of Cognitive Function in Elderly Patients. Contrast Media & Molecular Imaging. 2022; 2022:9871800. doi: 10.1155/2022/9871800.
  13. Damy T., Chouihed T., Delarche N., et al. Diagnosis and management of heart failure in older patients from hospitalization to discharge: a position paper. J Clinic Med. 2021;10(16):3519. doi: 10.3390/jcm10163519.
  14. McDonagh T.A., Metra M., Adamo M., et al. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599–726. doi: 10.1093/eurheartj/ehab368.
  15. McMurray J.J., Packer M., Desai A.S., et al. PARADIGM-HF Investigators and Committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371:993–1004.
  16. Velazquez E.J., Morrow D.A., DeVore A.D., et al. PIONEER-HF Investigators. Angiotensin-Neprilysin in Acute Decompensated Heart Failure. N Engel J Med. 2019;380(6):539–48. doi: 10.1056/NEJMoa1812851.
  17. Komajda M., Bohm M., Borer J.S., et al. Incremental benefit of drug therapies for chronic heart failure with reduced ejection fraction: a network meta-analysis. Eur J Heart Fail. 2018;20(9):1315–22. doi: 10.1002/ejhf.1234.
  18. Teramoto K., Tromp J., Lam C.S.P. Heart failure or heart success? Cardiovasc Res. 2021;117(3):e29–34. doi: 10.1093/cvr/cvab022.
  19. Packer M. SGLT2 inhibitors produce cardiorenal benefits by promoting adaptive cellular reprogramming to induce a state of fasting mimicry: a paradigm shift in understanding their mechanism of action. Diabetes Care. 2020;43(3):508–11. doi: 10.2337/dci19-0074.
  20. Kosiborod M.N., Jhund P.S., Docherty K.F., et all. Effects of Dapagliflozin on Symptoms, Function, and Quality of Life in Patients With Heart Failure and Reduced Ejection Fraction: Results From the DAPA-HF Trial. Circulation. 2020 Jan 14;141(2):90-99. doi: 10.1161/CIRCULATIONAHA.119.044138.
  21. Petrie M.C., Verma S., Dochertyet K.F., et al. Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes. JAMA. 2020;323(14):1353–68. doi: 10.1001/jama.2020.1906.
  22. Martinez F.A., Serenelli M., Nicolau J.C., et all. Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to Age: Insights From DAPA-HF. Circulation. 2020 Jan 14;141(2):100-111. doi: 10.1161/CIRCULATIONAHA.119.044133.
  23. Packer M., Anker S.D., Butler J., et al. Effect of Empagliflozin on the Clinical Stability of Patients with Heart Failure and a Reduced Ejection Fraction: The EMPEROR-Reduced Trial. Circulation. 2021;143(4):326–36. doi: 10.1161/CIRCULATIONAHA.120.051783.
  24. Packer M., Anker S.D., Butler J., et al. Empagliflozin in Patients With Heart Failure, Reduced Ejection Fraction, and Volume Overload. EMPEROR-Reduced Trial. J Am Coll Cardiol. 2021;77:1381–92. doi: 10.1016/j.jacc.2021.01.033.
  25. Butler J., Anker S.D., Filippatos G., et al. Empagliflozin and health-related quality of life outcomes in patients with heart failure with reduced ejection fraction: the EMPEROR Reduced trial. Eur Heart J. 2021;42(13):1203–12. doi: 10.1093/eurheartj/ ehaa1007.
  26. Bhatt D.L., Szarek M., Steg P.G., Cannon C.P., Leiter L.A., Mc-Guire D.K. et al. Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure. N Engl J Med. 2021;384(2):117–28. doi: 10.1056/NEJMoa2030183.
  27. McMurray J.J.V., Packer M. How Should We Sequence the Treatments for Heart Failure and a Reduced Ejection Fraction? A Redefinition of Edidence-Based Medicine. Circulation. 2020;143(9):875–77. doi: 10.1161/circulationaha.120.052926.
  28. Update to the 2017 ACC expert consensus decision pathway for optimization of heart failure treatment: answers to 10 pivotal issues about heart failure with reduced ejection fraction. J Am Coll Cardiol. 2021. doi: 10.1016/j.jacc.2020.11.022.
  29. Emdin M., Aimo A., Castiglione V., et al. Targeting Cyclic Guanosine Monophosphate to Treat Heart Failure. J Am Coll Cardiol. 2020;76(15):1795–807. doi: 10.1016/j.jacc.2020.08.031.
  30. Armstrong P.W., Pieske B., Anstrom K.J., et al. Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med. 2020;382(20):1883–93. doi: 10.1056/NEJMoa1915928.
  31. Anand I.S., Gupta P. Anemia and Iron Deficiency in Heart Failure: Current Concepts and Emerging Therapies. Circulation. 2018;138(1):80–98. doi: 10.1161/CIRCULATIONAHA.118.030099.
  32. Ponikowski P., Kirwan B.-A., Anker S.D., et al. Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial. Lancet (London, England). 2020;396(10266):1895–904. doi: 10.1016/S0140-6736(20)32339-4.
  33. Iacoviello M., Pugliese R., Correale M., et al. Optimization of Drug Therapy for Heart Failure With Reduced Ejection Fraction Based on Gender. Curr Heart Fail Rep. 2022;19(6):467–75. doi: 10.1007/s11897-022-00583-w.
  34. Li H., Hastings M.H., Rhee J., et al. Targeting Age-Related Pathways in Heart Failure. Исследование циркуляции. 2020;126(4):533–51. doi: 10.1161/circresaha.119.315889.
  35. Акчурин Р.С., Терещенко С.Н. Немеди-каментозное лечение хронической сердечной недостаточности. От интервенции к трансплантации. М.: Яровейс, 2022. [Akchurin R.S., Tereshchenko S.N. Non-drug treatment of chronic heart failure. From intervention to transplantation. M.: Yaroveys, 2022. (In Russ.)].
  36. Stolfo D., Sinagra G., Savarese G. Evidence-based therapy in elderly patients with reduced ejection fraction heart failure. Card Fail Rev. 2022;8:e16. doi: 10.15420/cfr.2021.34.
  37. Duong M.H., Gnjidic D., McLachlan A.J., et al. The Prevalence of Adverse Drug Reactions and Adverse Drug Events from Heart Failure Medications in Frail Older Adults: A Systematic Review. Drugs Aging. 2022;39(8):631–43. doi: 10.1007/s40266-022-00957-8.
  38. Pazan F., Weiss C., Wehling M., et al. The EURO-FORTA (Fit fOR The Aged) list: international consensus validation of a clinical tool for improved drug treatment in older people. Drugs Aging. 2018;35(1):61–71. doi: 10.1007/s40266-017-0514-2
  39. Орлова Я.А., Ткачёва О.Н., Арутюнов Г.П. и др. Особенности диагностики и лечения хронической сердечной недостаточности у пациентов пожилого и старческого возраста. Мнение экспертов Общества специалистов по сердечной недостаточности, Российской ассоциации геронтологов и гериатров и Евразийской ассоциации терапевтов. Кардиология. 2018;58(S12):42–72. [Orlova Ya.A., Tkache-va O.N., Arutyunov G.P., et al. Peculiarities of diagnosis and treatment of chronic heart failure in elderly and senile patients. Expert opinion of the Society of Heart Failure Specialists, the Russian Association of Gerontologists and Geriatricians and the Eurasian Association of Therapists. Kardiologiia. 2018;58(S12):42–72. (In Russ.)]. doi: 10.18087/cardio.2560
  40. Belialov F. Drug classification for patients with comorbidities. J Pharm Policy Pract. 2022 Sep 22;15(1):56. doi: 10.1186/s40545-022-00453-9.
  41. Тарловская Е.И., Омарова Ю.В. Анализ соответствия назначенной терапии системе EURO FORTA у полиморбидных пациентов пожилого и старческого возраста с хронической сердечной недостаточностью. Кардиология. 2021;61(11):57–64. [Tarlovskaya E.I., Omarova Yu.V. Analysis of the compliance of the prescribed therapy with the EURO FORTA system in elderly and senile polymorbid patients with chronic heart failure. Kardiologiya. 2021;61(11):57–64. (In Russ.)]. doi: 10.18087/cardio.2021. 11.n1619.
  42. Canepa M., Leporatti L., Persico L., et al. Frequency, characteristics and prognostic impact of hospital readmissions in elderly patients with heart failure: A population study from 2013 to 2017 in Liguria, Northern Italy. Int J Cardiol. 2022;363:111–18. doi: 10.1016/j.ijcard.2022.06.052.
  43. Стратегия социально-экономического развития Республики Коми на период до 2035 г. [Strategy for the socio-economic development of the Komi Republic for the period up to 2035. (In Russ.)]. URL: https://storage.strategy24.ru/files/news/201901/539d752dbf9cbaa9775d90705c744722.pdf
  44. Государственный доклад «О состоянии здоровья населения Республики Коми в 2019 году». Министерство здравоохранения Республики Коми. Сыктывкар, 2020 г.. 285 с. [State report «On the state of health of the population of the Komi Republic in 2019». Ministry of Health of the Republic of Komi. Syktyvkar, 2020 285 p. (In Russ.)]. URL: https://storage.strategy24.ru/files/news/201901/539d752dbf9cbaa9775d90705c744722.pdf

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies